ROMISET 500 MG INJ

About

ROMISET 500 MG INJ contains Romiplostim, a thrombopoietin (TPO) receptor agonist. It is a peptibody, a fusion protein that specifically binds to and activates the human TPO receptor, mimicking the action of endogenous thrombopoietin. This activation stimulates megakaryopoiesis, the process of platelet production, within the bone marrow. By increasing the number of megakaryocytes and their subsequent maturation, Romiplostim leads to a dose-dependent increase in platelet counts, which are crucial for normal blood clotting and preventing bleeding.

This medication is primarily used to treat chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to other treatments, such as corticosteroids, immunoglobulins, or splenectomy. Its targeted mechanism helps to restore and maintain adequate platelet levels, thereby significantly reducing the risk of bleeding events and improving the quality of life for individuals living with chronic ITP.

Uses

• Treatment of chronic immune thrombocytopenia (ITP).
• Increases platelet counts in ITP patients.
• Reduces the risk of bleeding in ITP.
• Used in adults refractory to other ITP treatments.

Directions For Use

Administer as a subcutaneous injection once weekly, as directed by a healthcare professional. Dose is adjusted based on platelet count.

Benefits

• Effectively increases platelet counts.
• Reduces the incidence of bleeding events in ITP.
• Offers a non-immunosuppressive treatment option.
• Convenient weekly subcutaneous administration.
• Improves quality of life for ITP patients.
• Helps avoid splenectomy in some cases.

Side Effects

• Headache
• Arthralgia
• Dizziness
• Insomnia
• Myalgia
• Paresthesia
• Abdominal pain
• Diarrhea
• Nausea
• Increased risk of thrombosis
• Bone marrow reticulin formation
• Injection site reactions

Safety Measures

• Alcohol - No specific interaction, but excessive alcohol may exacerbate bleeding risk in ITP patients.
• Pregnancy - Use only if the potential benefit justifies the potential risk to the fetus; limited human data available.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if it is excreted in human milk and potential for adverse effects on infant.
• Liver - Use with caution in patients with liver impairment; monitor liver function tests periodically.
• Kidney - No specific dose adjustment required in patients with renal impairment.
• Lung - No direct lung effects, but monitor for any new or worsening respiratory symptoms, especially if thrombosis is a concern.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.